Scientists re-engineer Patients' own cells to hunt deadly childhood cancers
NCT ID NCT04539366
Summary
This early-stage study is testing a new cell therapy called GD2CART for children and young adults whose neuroblastoma or osteosarcoma has returned or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to recognize cancer, and infuse them back into the body. The main goals are to find a safe dose and see if these 're-trained' cells can help the immune system find and kill the cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
Children's Hospital Los Angeles
Los Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.